28/10/2024 – AB Science today announced that the European Patent Office has issued a Notice of Allowance for a patent relating to methods of treating sickle cell disease with masitinib

17/10/2024 – AB Science today announces that the European Medicines Agency (EMA) confirmed a negative opinion for the conditional marketing authorization of masitinib in the treatment of amyotrophic lateral sclerosis

10/10/2024 – AB Science today reports its revenues for the first half of 2024 and provides an update on its activities

09/10/2024 – AB Science announces today that it has completed the settlement and delivery of the capital increase announced on September 30, 2024

30/09/2024 – The Company will publish its financial report for the first half of 2024 on Monday 7 October 2024

30/09/2024 – AB Science announces today the success of a capital increase by private placement for an amount of 5 million euros